Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 522535768 series 3525243
Content provided by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
What happens when cell therapy innovation meets real patient urgency? In this conversation, the barriers between scientist and patient all but vanish, bringing clarity—and a new sense of mission—to some of the biggest problems facing advanced therapy manufacturing and delivery.
Meet Jesús Zurdo, a biotech leader whose three decades of experience in innovation took on a whole new perspective when he became a leukemia patient himself. Seamlessly straddling the worlds of industry and patient care, Jesús Zurdo brings a refreshingly honest, systems-level view to cell therapies, manufacturing bottlenecks, and the realities of getting therapies from the lab to bedside.
Topics discussed:
- Experiences and lessons from stem cell registries and point-of-care manufacturing models (03:15)
- Challenges and potential of autologous and allogeneic cell therapies, including scalability and accessibility (06:08)
- The promise and limitations of in vivo cell therapy, delivery risks and patient safety (07:06)
- Reflections on current trends in manufacturing automation, delivery platforms, and the risk of overengineering (09:49)
- Barriers to wider adoption of advanced cell therapies, including hospital infrastructure and economic constraints (13:31)
- The case for earlier lines of treatment with new modalities and value in learning from actual patient experiences (14:30)
- The importance of integrating voices of patients, clinicians, and developers when solving complex problems (17:31)
- Why urgency and remembering our future roles as patients should guide therapy development (18:51)
Ready for bioprocessing to serve patients, yours included? For more insights and hands-on support, please subscribe so you never miss the next perspective-shifting episode.
Connect with Jesús Zurdo:
LinkedIn: https://www.linkedin.com/in/jesuszurdo
Email: [email protected]
Next step:
Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call
213 episodes
))
